Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Ticker
CMMB
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$11.15M
52-week range
$0.92 - $2.99

Valuation

Share price
$1.55 (close of Nov 18, 2026)
P/E (TTM)
-1.08x
Price to book
0.90x
Price to free cash flow
-1.00x
Enterprise value
$748.01K
Book value per share
$1.71

Price performance

PeriodChange
1 day-5.49%
5 days+14.81%
1 month+23.02%
3 months-18.85%
6 months-4.32%
Year to date-6.06%
1 year-43.22%
3 years-32.02%
5 years-95.73%
All time-99.78%

Short interest

As of
Oct 30, 2026
Short % of float
0.07%
Shares short
5.14K
Days to cover
0.11
Change since prior report
-63.00%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-72.93%
Return on assets
-65.12%

Cash flow and balance sheet

Free cash flow yield (TTM)
-99.87%
Current ratio
9.08x
Net debt to EBITDA
1.10x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
EBITDA
-$111.93M
Net income
-$8.99M
Earnings per share
$-1.44
Research and development
$5.83M
Shares outstanding
6.38M

Income statement by year

Period endNet incomeEPS
2025-12-31-$8.99M-$1.44
2024-12-31-$13.95M-$3.12
2023-12-31-$24.22M-$8.24
2022-12-31-$27.65M-$9.68
2021-12-31-$12.48M-$4.80
2020-12-31-$5.95M$3.52
2019-12-31-$27.12M$1,011.20
2018-12-31-$13.80M$1,395.20
2017-12-31-$9.81M-$1.70
2016-12-31-$4.74M-$1.24

Margins and returns by year

Period endReturn on equityReturn on capital
2025-12-31-72.93%-
2024-12-31-103.01%-
2023-12-31-142.50%-139.29%*
2022-12-31-76.32%-75.87%*
2021-12-31-20.30%-20.19%*
2020-12-31-55.09%53.05%*
2019-12-31-219.22%201.15%*
2018-12-31-140.72%-113.12%
2016-12-31-144.01%-

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCash
2025-12-31$10.40M
2024-12-31$14.30M
2023-12-31$9.29M
2022-12-31$13.52M
2021-12-31$15.19M
2020-12-31$11.67M
2019-12-31$17.57M
2018-12-31$7.52M
2017-12-31$1.45M
2016-12-31$4.56M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31-$11.13M$623.00K
2024-12-31-$15.39M$617.00K
2023-12-31-$23.61M$1.49M
2022-12-31-$20.44M$3.21M
2021-12-31-$12.61M$2.02M
2020-12-31-$5.28M$130.00K
2019-12-31-$16.55M$1.16M
2018-12-31-$14.44M$1.93M
2017-12-31-$8.55M$730.00K
2016-12-31-$3.81M$270.00K

Investor relations

Next earnings report

Next confirmed report
Nov 19, 2026

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-05Sep 2026-
2026-10-08Sep 2026-
2026-08-19Jun 2026-
2026-05-14Mar 2026-
2026-03-19Dec 2025-$0.20
2025-08-14Jun 2025-$0.20
2025-05-15Mar 2025-$0.20
2025-03-03Dec 2024-$0.20

Filings and sources

Company website
chemomab.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades